MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Experimental therapeutics"

  • MDS Virtual Congress 2021

    Homeostatic Improvement of Brain Bioenergetic Metabolism in Parkinson’s Disease: Results From A Phase 2 REPAIR-PD Clinical Trial With CNM-Au8

    R. Glanzman, J. Ren, Phd, R. Dewey, Iii, A. Rynders, K. Ho, Phd, R. Dewey, JR. (Holladay, USA)

    Objective: To determine the effects of the nanocatalytic drug, CNM-Au8, on brain energy metabolites in Parkinson’s Disease. Background: Converging lines of evidence are identifying brain…
  • MDS Virtual Congress 2020

    Weeding Through the Haze: A Survey on Cannabis Use Among People with Parkinson’s Disease

    M. Feeney, B. Kluger, A. Stoessl, D. Bega, S. Gilbert, A. Hosang, E. Ogren, K. Schroeder, C. Evers, J. Beck (New York, NY, USA)

    Objective: To identify themes in cannabis use among people with Parkinson’s disease to inform medical recommendations and the design of future clinical trials. Background: Parkinson’s…
  • MDS Virtual Congress 2020

    Pridopidine for the Treatment of Early Huntington’s Disease

    M. Geva, R. Reilmann, C. Olanow, M. Leinonen, Y. Cohen, P. Meyer, A. McGarry, O. Sabri, M. Hayden, K. Kieburtz (Herzliya, Israel)

    Objective: Assess the efficacy of pridopidine 45 mg bid for maintenance of total functional capacity (TFC) and motor function in early HD patients. Background: Pridopidine…
  • MDS Virtual Congress 2020

    Translatable biomarkers in gene therapy for Huntington’s Disease: learnings from pre-clinical studies

    A. Valles, M. Evers, A. Stam, M. Sogorb-Gonzales, C. Brouwers, C. Vendrell, S. Acar-Broekmans, V. Fodale, A. Bresciani, R. Nieuwland, Z. Ellederova, J. Motlik, M. de Haan, B. Leavitt, S. van Deventer, P. Konstantinova (Amsterdam, Netherlands)

    Objective: We have developed AAV5-miHTT, a recombinant AAV-based gene therapy expressing an engineered microRNA that specifically binds to HTT exon1, resulting in lowering of both…
  • MDS Virtual Congress 2020

    Effect of herbal medicine against Parkinson’s Diseases- An in silico studies

    S. Subramani, Y. Gupta, R. Sharma, P. Prasad (Gwalior, India)

    Objective: To evaluate the effect of the bioactive compounds of Gymnema sylvestre on treatment of Parkinson’s diseases. Background: Neurodegenerative diseases, such as Parkinson’s and Alzheimer’s,…
  • MDS Virtual Congress 2020

    Gut Microbiota in Parkinson’s disease: influences of device-assisted therapies

    M. Lubomski, X. Xu, A. Holmes, J. Yang, R. Davis, C. Sue (Sydney, Australia)

    Objective: To determine the temporal stability of gut microbiota (GM) profiles around the acute establishment of advanced Parkinson's disease (PD) therapies and describe resulting alterations in…
  • MDS Virtual Congress 2020

    Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease

    M. Geva, A. McGarry, Y. Cohen, T. Johnston, M. de Somer, K. Kieburtz, M. Hayden, J. Brotchie, C. Olanow (Herzliya, Israel)

    Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…
  • MDS Virtual Congress 2020

    Therapeutic Benefits of Music for Three Types of Neurological Disorders: an fNIRS Study Protocol for Controlled Trial in Dalian, China, Part 1-Parkinson’s Disease

    LL. Pu, Z.H Liang, W.C Tang, F.Y Cong, B.W Zhang, N.K Qureshi, J. Ly, T. Li (Dalian, China)

    Objective: It is investigated that the external auditory stimuli affect motor synchronization and control in patients with PD,and further studied that how music therapy or other…
  • MDS Virtual Congress 2020

    A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects with Parkinson’s Disease on Stable Dopaminergic Treatment (TEAL Study)

    E. Rawner, J. Powell, S. Minami, K. Tang, V. Klutzaritz, E. McCaskill Newman, J. Hannestad (San Carlos, CA, USA)

    Objective: Assessment of efficacy and safety in subjects with Parkinson’s disease (PD) following treatment for 12 weeks with placebo or AKST4290, a highly specific and…
  • MDS Virtual Congress 2020

    Deep learning approach for Parkinson’s disease classification from facial expressions: A pilot feasibility study

    O. Phokaewvarangkul, P. Vateekul, D. Surangsrirat, R. Bhidayasiri (Bangkok, Thailand)

    Objective: To apply deep learning and traditional machine learning approaches to images of different facial expressions from patients and controls to aid in the prediction…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley